Subsequently, pERKT188 has been shown to trigger the activation of nuclear ERK targets such as Elk1, MSK, and c-myc, targets that not only promote cancer but are known to induce cardiomyocyte hypertrophy [60,61,62]. Here, MAPK1 is linked to cancer.